Anthony Atala

ORCID: 0000-0001-8186-2160
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Tissue Engineering and Regenerative Medicine
  • Urological Disorders and Treatments
  • Electrospun Nanofibers in Biomedical Applications
  • 3D Printing in Biomedical Research
  • Pluripotent Stem Cells Research
  • Renal and related cancers
  • Mesenchymal stem cell research
  • Bladder and Urothelial Cancer Treatments
  • Prostate Cancer Treatment and Research
  • Pediatric Urology and Nephrology Studies
  • Biomedical Ethics and Regulation
  • Sperm and Testicular Function
  • Urinary Bladder and Prostate Research
  • Prostate Cancer Diagnosis and Treatment
  • Reproductive Biology and Fertility
  • Additive Manufacturing and 3D Printing Technologies
  • Bone Tissue Engineering Materials
  • Urologic and reproductive health conditions
  • Sexual Differentiation and Disorders
  • Sexual function and dysfunction studies
  • Epigenetics and DNA Methylation
  • Pelvic floor disorders treatments
  • Innovative Microfluidic and Catalytic Techniques Innovation
  • Hormonal and reproductive studies
  • Wound Healing and Treatments

Wake Forest University
2015-2024

Forest Institute
2015-2024

Atrium Health Wake Forest Baptist
2012-2024

Virginia Tech - Wake Forest University School of Biomedical Engineering & Sciences
2007-2023

Sungkyunkwan University
2021

Chonnam National University Hospital
2021

John Wiley & Sons (United States)
2016-2020

American College of Surgeons
2005-2020

Memorial Sloan Kettering Cancer Center
2020

Charlottesville Medical Research
2018-2020

10.1038/nbt.2958 article EN Nature Biotechnology 2014-08-01

Significance Monitoring human organ-on-a-chip systems presents a significant challenge, where the capability of in situ continual monitoring organ behaviors and their responses to pharmaceutical compounds over extended periods time is critical understanding dynamics drug effects therefore accurate prediction reactions. In this work, we report fully integrated modular physical, biochemical, optical sensing platform, interfaced through fluidics-routing breadboard with multi–organ-on-a-chip...

10.1073/pnas.1612906114 article EN Proceedings of the National Academy of Sciences 2017-03-06

A major roadblock to successful organ bioengineering is the need for a functional vascular network within engineered tissue. Here, we describe fabrication of three-dimensional, naturally derived scaffolds with an intact tree. Livers from different species were perfused detergent selectively remove cellular components tissue while preserving extracellular matrix and network. The decellularized was able withstand fluid flow that entered through central inlet vessel, branched into extensive...

10.1002/hep.24067 article EN Hepatology 2010-11-12

Abstract Stem cells obtained from amniotic fluid show high proliferative capacity in culture and multilineage differentiation potential. Because of the lack significant immunogenicity ability fluid-derived stem (AFS) to modulate inflammatory response, we investigated whether they could augment wound healing a mouse model skin regeneration. We used bioprinting technology treat full-thickness wounds nu/nu mice. AFS bone marrow-derived mesenchymal (MSCs) were resuspended fibrin-collagen gel...

10.5966/sctm.2012-0088 article EN cc-by-nc Stem Cells Translational Medicine 2012-10-29

Bioprinting is an emerging technique used to fabricate viable, 3D tissue constructs through the precise deposition of cells and hydrogels in a layer-by-layer fashion. Despite ability mimic native properties tissue, printed that are composed naturally-derived biomaterials still lack structural integrity adequate mechanical for use vivo, thus limiting their development load-bearing engineering applications, such as cartilage. Fabrication viable using novel multi-head system provides combine...

10.1088/1758-5082/5/1/015001 article EN Biofabrication 2012-11-21

The inadequacy of animal models in correctly predicting drug and biothreat agent toxicity humans has resulted a pressing need for vitro that can recreate the vivo scenario. One most important organs assessment is liver. Here, we report development liver-on-a-chip platform long-term culture three-dimensional (3D) human HepG2/C3A spheroids assessment. bioreactor design allowed situ monitoring environment by enabling direct access to hepatic construct during experiment without compromising...

10.1088/1758-5090/8/1/014101 article EN Biofabrication 2016-01-12

In the United States alone, there are approximately 500,000 burn injuries that require medical treatment every year. Limitations of current treatments necessitate development new methods can be applied quicker, result in faster wound regeneration, and yield skin is cosmetically similar to undamaged skin. The hydrogel biomaterials bioprinting deposition technologies has provided a platform address this need. Herein we evaluated characteristics twelve hydrogels determine their suitability for...

10.1002/jbm.a.34326 article EN Journal of Biomedical Materials Research Part A 2012-08-31

Abstract Many drugs have progressed through preclinical and clinical trials been available – for years in some cases before being recalled by the FDA unanticipated toxicity humans. One reason such poor translation from drug candidate to successful use is a lack of model systems that accurately recapitulate normal tissue function human organs their response compounds. Moreover, tissues body do not exist isolation, but reside highly integrated dynamically interactive environment, which actions...

10.1038/s41598-017-08879-x article EN cc-by Scientific Reports 2017-08-14

Abstract Here, we report an intrinsic property of gold nanoparticles (nanogold): they can interact selectively with heparin-binding glycoproteins and inhibit their activity. Gold specifically bound vascular permeability factor/vascular endothelial growth factor (VPF/VEGF)-165 basic fibroblast factor, two cell mitogens mediators angiogenesis resulting in inhibition endothelial/fibroblast proliferation vitro VEGF-induced as well vivo. In contrast, nanogold did not VEGF-121 or epidermal...

10.1158/1078-0432.ccr-04-2482 article EN Clinical Cancer Research 2005-05-01
Coming Soon ...